Search for: "Novartis, Ltd., Inc."
Results 1 - 20
of 171
Sort by Relevance
|
Sort by Date
16 Apr 2024, 8:42 am
., Ltd. v. [read post]
12 Mar 2024, 12:46 pm
., Inc. v. [read post]
22 Jan 2024, 1:16 pm
., Ltd. [read post]
11 Oct 2023, 1:23 am
Ltd. [read post]
8 May 2023, 5:24 pm
Novartis Pharms. [read post]
5 Apr 2023, 5:18 am
Similarly, Hacon HHJ stated in Teva v Novartis [2022] EWHC 2847 (Pat): “It seems that there was little or no interaction between Novartis’ three experts during the preparation of their evidence. [read post]
13 Mar 2023, 2:29 pm
” Novartis AG v. [read post]
26 Sep 2022, 4:49 am
Sanofi as well as with the likely upcoming petition in Novartis Pharm. [read post]
19 Jul 2022, 7:46 am
., Ltd. and HEC Pharm USA Inc., vacated its prior decision, and reversed the district court’s judgment that the claims of patent at issue were not invalid (Novartis Pharmaceuticals Corporation. v. [read post]
12 Jul 2022, 2:08 am
Defendants HEC Pharm Co., Ltd. and HEC Pharm USA Inc. appealed. [read post]
21 Jun 2022, 2:18 pm
Accord Healthcare, Inc. granting a petition for rehearing from appellant HEC Pharm Co., Ltd. [read post]
21 Jun 2022, 2:18 pm
Accord Healthcare, Inc. granting a petition for rehearing from appellant HEC Pharm Co., Ltd. [read post]
5 Jan 2022, 6:40 pm
Ltd. v. [read post]
4 Jan 2022, 4:15 am
Patent No. 9,187,405 is not invalid and that HEC Pharm Co., Ltd. and HEC Pharm USA Inc. [read post]
4 Jan 2022, 4:15 am
Patent No. 9,187,405 is not invalid and that HEC Pharm Co., Ltd. and HEC Pharm USA Inc. [read post]
5 Aug 2021, 12:12 pm
Labs., Ltd. v. [read post]
24 May 2021, 7:34 am
The plaintiffs have accused Ranbaxy of delaying the launch of generic versions of Novartis AG’s high blood pressure drug Diovan, Pfizer Inc’s acid reflux drug Nexium and Genentech Inc’s antiviral drug Valcyte. [read post]
27 Jan 2021, 11:07 am
Novartis. [read post]
8 Jan 2021, 3:49 am
Ltd., 853 F.3d 1316, 1328 (Fed. [read post]
3 Aug 2020, 7:02 am
Where there are specialists with a focus on the kind of work with which a patent is concerned, they are the relevant addressees of the patent and their specialist skills are attributed to the notional skilled person, even if the patent might also be of a broader application and of interest to non-specialists (Medimmune Ltd v Novartis Pharmaceuticals UK Ltd [2013] RPC 27). [read post]
